{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:56:17Z","timestamp":1788432977597,"version":"build-2803163510"},"reference-count":75,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) cells are addicted to MYC and its direct transactivation targets IRF4 for proliferation and survival. MYC and IRF4 are still considered \u201cundruggable,\u201d as most small-molecule inhibitors suffer from low potency, suboptimal pharmacokinetic properties, and undesirable off-target effects. Indirect inhibition of MYC\/IRF4 emerges as a therapeutic vulnerability in MM. Here, we uncovered an unappreciated tumor-suppressive role of C-terminal binding protein 2 (CTBP2) in MM via strong inhibition of the MYC-IRF4 axis. In contrast to epithelial cancers, CTBP2 is frequently downregulated in MM, in association with shortened survival, hyperproliferative features, and adverse clinical outcomes. Restoration of CTBP2 exhibited potent antitumor effects against MM in\u00a0vitro and in\u00a0vivo, with marked repression of the MYC-IRF4 network genes. Mechanistically, CTBP2 impeded the transcription of MYC and IRF4 by histone H3 lysine 27 deacetylation (H3K27ac) and indirectly via activation of the MYC repressor IFIT3. In addition, activation of the interferon gene signature by CTBP2 suggested its concomitant immunomodulatory role in MM. Epigenetic studies have revealed the contribution of polycomb-mediated silencing and DNA methylation to CTBP2 inactivation in MM. Notably, inhibitors of Enhance of zeste homolog 2, histone deacetylase, and DNA methyltransferase, currently under evaluation in clinical trials, were effective in restoring CTBP2 expression in MM. Our findings indicated that the loss of CTBP2 plays an essential role in myelomagenesis and deciphers an additional mechanistic link to MYC-IRF4 dysregulation in MM. We envision that the identification of novel critical regulators will facilitate the development of selective and effective approaches for treating this MYC\/IRF4-addicted malignancy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010218","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T22:54:40Z","timestamp":1709938480000},"page":"2217-2234","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7712-3768","authenticated-orcid":false,"given":"Coty Hing Yau","family":"Cheung","sequence":"first","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Keung","family":"Cheng","sequence":"additional","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-2513","authenticated-orcid":false,"given":"Kam Tong","family":"Leung","sequence":"additional","affiliation":[{"name":"2Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Yan","family":"Ho","sequence":"additional","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Luo","sequence":"additional","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel Yuet Fong","family":"Kam","sequence":"additional","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Xia","sequence":"additional","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Shek Kong","family":"Wan","sequence":"additional","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-4873","authenticated-orcid":false,"given":"Herbert Augustus","family":"Pitts","sequence":"additional","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Pui Ha","family":"Chan","sequence":"additional","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce Sin","family":"Cheung","sequence":"additional","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Siu Ming","family":"Wong","sequence":"additional","affiliation":[{"name":"3Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bing","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Loma Linda University, Loma Linda, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret Heung Ling","family":"Ng","sequence":"additional","affiliation":[{"name":"1Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"},{"name":"5State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"4","key":"2024051415260935800_bib1","first-page":"842","article-title":"MYC inhibitors in multiple myeloma","volume":"4","author":"Mart\u00ednez-Mart\u00edn","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"7201","key":"2024051415260935800_bib2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"12","key":"2024051415260935800_bib3","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2011-08-371567","article-title":"Addiction to c-MYC in multiple myeloma","volume":"120","author":"Holien","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2024051415260935800_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"May","key":"2024051415260935800_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2018.07.025","article-title":"IRF4 in multiple myeloma\u2014biology, disease and therapeutic target","volume":"72","author":"Agnarelli","year":"2018","journal-title":"Leuk Res"},{"key":"2024051415260935800_bib6","doi-asserted-by":"crossref","first-page":"103756","DOI":"10.1016\/j.ebiom.2021.103756","article-title":"Therapeutic targeting of \u201cundruggable\u201d MYC","volume":"75","author":"Llombart","year":"2022","journal-title":"EBioMedicine"},{"issue":"12","key":"2024051415260935800_bib7","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/leu.2015.169","article-title":"MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib","volume":"29","author":"Xie","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2024051415260935800_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2012.269","article-title":"MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC","volume":"27","author":"Min","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"2024051415260935800_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41408-021-00589-y","article-title":"Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation","volume":"11","author":"Mori","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"2024051415260935800_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2643-3230.BCD-20-0108","article-title":"Lysine demethylase 5A is required for MYC-driven transcription in multiple myeloma","volume":"2","author":"Ohguchi","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"39","key":"2024051415260935800_bib11","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1038\/onc.2008.162","article-title":"Inhibition of transcriptional activation and cell proliferation activities of adenovirus E1A by the unique N-terminal domain of CtBP2","volume":"27","author":"Zhao","year":"2008","journal-title":"Oncogene"},{"issue":"22","key":"2024051415260935800_bib12","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1158\/0008-5472.CAN-14-1030","article-title":"CtBP2 modulates the androgen receptor to promote prostate cancer progression","volume":"74","author":"Takayama","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"2024051415260935800_bib13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1593\/neo.121674","article-title":"BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2","volume":"15","author":"May","year":"2013","journal-title":"Neoplasia"},{"issue":"3","key":"2024051415260935800_bib14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","article-title":"Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CTBP2","volume":"39","author":"Cui","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"2024051415260935800_bib15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/mt.2011.258","article-title":"Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone","volume":"20","author":"Meng","year":"2012","journal-title":"Mol Ther"},{"issue":"6","key":"2024051415260935800_bib16","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A\u00a0validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2024051415260935800_bib17","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1158\/0008-5472.CAN-06-4046","article-title":"Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling","volume":"67","author":"Chng","year":"2007","journal-title":"Cancer Res"},{"issue":"8","key":"2024051415260935800_bib18","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2024051415260935800_bib19","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2024051415260935800_bib20","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1128\/MCB.02402-05","article-title":"Mechanisms directing the nuclear localization of the CtBP family proteins","volume":"26","author":"Verger","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2024051415260935800_bib21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3324\/haematol.2010.033456","article-title":"A\u00a0high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines","volume":"96","author":"Moreaux","year":"2011","journal-title":"Haematologica"},{"issue":"17","key":"2024051415260935800_bib22","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood-2015-05-644039","article-title":"Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System","volume":"126","author":"Kuiper","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2024051415260935800_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2024051415260935800_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1097-2765(01)00275-1","article-title":"Myc requires distinct E2F activities to induce S phase and apoptosis","volume":"8","author":"Leone","year":"2001","journal-title":"Mol Cell"},{"issue":"10","key":"2024051415260935800_bib25","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1128\/MCB.20.10.3497-3509.2000","article-title":"Involvement of Myc activity in a G1\/S-promoting mechanism parallel to the pRb\/E2F pathway","volume":"20","author":"Santoni-Rugiu","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2024051415260935800_bib26","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1038\/ncomms5750","article-title":"Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control","volume":"5","author":"Dong","year":"2014","journal-title":"Nat Commun"},{"issue":"2-3","key":"2024051415260935800_bib27","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejphar.2011.09.031","article-title":"Involvement of Chk1\u2013Cdc25A-cyclin A\/CDk2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells","volume":"670","author":"Tu","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"2024051415260935800_bib28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/187152012800617678","article-title":"The role of CDC25A in the regulation of cell proliferation and apoptosis","volume":"12","author":"Shen","year":"2012","journal-title":"Anticancer Agents Med Chem"},{"issue":"5","key":"2024051415260935800_bib29","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/sj.leu.2404602","article-title":"Significant impact of survivin on myeloma cell growth","volume":"21","author":"Romagnoli","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"2024051415260935800_bib30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1054\/bjoc.2000.1655","article-title":"Telomerase activity in plasma cell dyscrasias","volume":"84","author":"Xu","year":"2001","journal-title":"Br J Cancer"},{"issue":"9","key":"2024051415260935800_bib31","doi-asserted-by":"crossref","first-page":"e12487-8","DOI":"10.1371\/journal.pone.0012487","article-title":"Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms","volume":"5","author":"Brennan","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"2024051415260935800_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2011.05.017","article-title":"miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma","volume":"309","author":"Chen","year":"2011","journal-title":"Cancer Lett"},{"issue":"50","key":"2024051415260935800_bib33","doi-asserted-by":"crossref","first-page":"19678","DOI":"10.1073\/pnas.0811166106","article-title":"MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc","volume":"105","author":"Aguda","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"2024051415260935800_bib34","doi-asserted-by":"crossref","first-page":"36613","DOI":"10.1074\/jbc.M603550200","article-title":"Changes in C-terminal binding protein 2 (CtBP2) corepressor complex induced by E1A and modulation of E1A transcriptional activity by CtBP2","volume":"281","author":"Zhao","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"2024051415260935800_bib35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tig.2016.02.002","article-title":"Deciphering ENCODE","volume":"32","author":"Diehl","year":"2016","journal-title":"Trends Genet"},{"issue":"1","key":"2024051415260935800_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41420-020-00400-0","article-title":"Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis","volume":"7","author":"Ishiguro","year":"2021","journal-title":"Cell Death Discov"},{"issue":"1","key":"2024051415260935800_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3324\/haematol.2018.191262","article-title":"DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling","volume":"104","author":"Ishiguro","year":"2019","journal-title":"Haematologica"},{"issue":"7034","key":"2024051415260935800_bib38","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nature03464","article-title":"IRF-7 is the master regulator of type-I interferon-dependent immune responses","volume":"434","author":"Honda","year":"2005","journal-title":"Nature"},{"issue":"3","key":"2024051415260935800_bib39","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1038\/bcj.2017.27","article-title":"Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control","volume":"7","author":"Pawlyn","year":"2017","journal-title":"Blood Cancer J"},{"issue":"44","key":"2024051415260935800_bib40","doi-asserted-by":"crossref","first-page":"16448","DOI":"10.1073\/pnas.0607830103","article-title":"RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins","volume":"103","author":"Xiao","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024051415260935800_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2019.03.011","article-title":"Molecular mechanisms directing PRC2 recruitment and H3K27 methylation","volume":"74","author":"Laugesen","year":"2019","journal-title":"Mol Cell"},{"issue":"6","key":"2024051415260935800_bib42","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","article-title":"DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation","volume":"8","author":"Miranda","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2024051415260935800_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/aps.2013.161","article-title":"EZH2: biology, disease, and structure-based drug discovery","volume":"35","author":"Tan","year":"2014","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"2024051415260935800_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/0008-5472.CAN-07-2531","article-title":"Genome-wide transcriptional response to 5-aza-2\u2032-deoxycytidine and trichostatin A in multiple myeloma cells","volume":"68","author":"Heller","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"2024051415260935800_bib45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024051415260935800_bib46","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1634\/theoncologist.2017-0644","article-title":"Panobinostat and multiple myeloma in 2018","volume":"23","author":"Yee","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"2024051415260935800_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1097-2765(02)00443-4","article-title":"CtBP, an unconventional transcriptional corepressor in development and oncogenesis","volume":"9","author":"Chinnadurai","year":"2002","journal-title":"Mol Cell"},{"issue":"8","key":"2024051415260935800_bib48","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/bies.1097","article-title":"The CtBP family: enigmatic and enzymatic transcriptional co-repressors","volume":"23","author":"Turner","year":"2001","journal-title":"Bioessays"},{"issue":"12","key":"2024051415260935800_bib49","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1038\/sj.emboj.7601153","article-title":"C-terminal-binding protein directly activates and represses Wnt transcriptional targets in Drosophila","volume":"25","author":"Fang","year":"2006","journal-title":"EMBO J"},{"issue":"6","key":"2024051415260935800_bib50","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4149\/neo_2018_171220N828","article-title":"CtBP2 promotes proliferation and reduces drug sensitivity in non-small cell lung cancer via the Wnt\/\u03b2-catenin pathway","volume":"65","author":"Wang","year":"2018","journal-title":"Neoplasma"},{"issue":"2","key":"2024051415260935800_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3892\/or.2021.8240","article-title":"CtBP2 interacts with TGIF to promote the progression of esophageal squamous cell cancer through the Wnt\/\u03b2-catenin pathway","volume":"47","author":"Ju","year":"2022","journal-title":"Oncol Rep"},{"issue":"8","key":"2024051415260935800_bib52","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/08880018.2020.1798572","article-title":"Low expression of CTBP2 and CASP8AP2 predicts risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a retrospective cohort study","volume":"37","author":"Cui","year":"2020","journal-title":"Pediatr Hematol Oncol"},{"issue":"9","key":"2024051415260935800_bib53","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/s41375-021-01151-2","article-title":"Low CtBP2 expression is associated with a stem cell-like signature and adverse clinical outcome in childhood B-cell lymphoblastic leukemia","volume":"35","author":"Chun","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2024051415260935800_bib54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1515\/bmc-2014-0027","article-title":"C-terminal binding proteins: central players in development and disease","volume":"5","author":"Stankiewicz","year":"2014","journal-title":"Biomol Concepts"},{"issue":"10","key":"2024051415260935800_bib55","doi-asserted-by":"crossref","first-page":"e354-10","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6","key":"2024051415260935800_bib56","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"2024051415260935800_bib57","doi-asserted-by":"crossref","first-page":"e10483","DOI":"10.7554\/eLife.10483","article-title":"Bromodomain inhibition of the transcriptional coactivators CBP\/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma","volume":"5","author":"Conery","year":"2016","journal-title":"Elife"},{"key":"2024051415260935800_bib58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.neulet.2017.02.006","article-title":"Down-regulation of C-terminal binding protein 2 (CtBP2) inhibits proliferation, migration, and invasion of human SHSY5Y cells in\u00a0vitro","volume":"647","author":"Nan","year":"2017","journal-title":"Neurosci Lett"},{"issue":"1","key":"2024051415260935800_bib59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.gene.2014.05.032","article-title":"CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling","volume":"546","author":"Zhang","year":"2014","journal-title":"Gene"},{"issue":"1","key":"2024051415260935800_bib60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3324\/haematol.13426","article-title":"MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells","volume":"94","author":"Brito","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"2024051415260935800_bib61","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"key":"2024051415260935800_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2121-7-35","article-title":"Role of the unique N-terminal domain of CtBP2 in determining the subcellular localisation of CtBP family proteins","volume":"7","author":"Bergman","year":"2006","journal-title":"BMC Cell Biol"},{"issue":"7","key":"2024051415260935800_bib63","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1074\/jbc.M509051200","article-title":"Acetylation by p300 regulates nuclear localization and function of the transcriptional corepressor CtBP2","volume":"281","author":"Zhao","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"15","key":"2024051415260935800_bib64","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/MCB.22.15.5296-5307.2002","article-title":"Overlapping and unique roles for C-terminal binding protein 1 (CtBP1) and CtBP2 during mouse development","volume":"22","author":"Hildebrand","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2024051415260935800_bib65","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.cell.2014.10.050","article-title":"A\u00a0proteome-scale map of the human interactome network","volume":"159","author":"Rolland","year":"2014","journal-title":"Cell"},{"issue":"1-2","key":"2024051415260935800_bib66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.18632\/genesandcancer.2","article-title":"CtBP2 proteome: role of CtBP in E2F7-mediated repression and cell proliferation","volume":"5","author":"Zhao","year":"2014","journal-title":"Genes Cancer"},{"issue":"8","key":"2024051415260935800_bib67","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/stem.2046","article-title":"Ctbp2 modulates NuRD-mediated deacetylation of H3K27 and facilitates PRC2-mediated H3K27me3 in active embryonic stem cell genes during exit from pluripotency","volume":"33","author":"Kim","year":"2015","journal-title":"Stem Cells"},{"key":"2024051415260935800_bib68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-2199-10-89","article-title":"Interaction of ZEB and histone deacetylase with the PLDLS-binding cleft region of monomeric C-terminal binding protein 2","volume":"10","author":"Zhao","year":"2009","journal-title":"BMC Mol Biol"},{"issue":"1","key":"2024051415260935800_bib69","doi-asserted-by":"crossref","first-page":"20-9","DOI":"10.1186\/s40164-017-0081-6","article-title":"Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today\u2019s treat-to-target era","volume":"6","author":"Zhang","year":"2017","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"2024051415260935800_bib70","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1089\/jir.2007.0021","article-title":"Antiproliferative activity of the human IFN-\u03b1-inducible protein IFI44","volume":"27","author":"Hallen","year":"2007","journal-title":"J\u00a0Interferon Cytokine Res"},{"issue":"31","key":"2024051415260935800_bib71","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1038\/onc.2017.79","article-title":"PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4","volume":"36","author":"Ueno","year":"2017","journal-title":"Oncogene"},{"issue":"9","key":"2024051415260935800_bib72","doi-asserted-by":"crossref","first-page":"e106788","DOI":"10.1371\/journal.pone.0106788","article-title":"Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"31","key":"2024051415260935800_bib73","doi-asserted-by":"crossref","first-page":"21930","DOI":"10.18632\/oncotarget.25128","article-title":"EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes","volume":"9","author":"Harding","year":"2018","journal-title":"Oncotarget"},{"key":"2024051415260935800_bib74","doi-asserted-by":"crossref","first-page":"11772719211067972","DOI":"10.1177\/11772719211067972","article-title":"Evaluation of a prognostic epigenetic classification system in chronic lymphocytic leukemia patients","volume":"17","author":"Grimm","year":"2022","journal-title":"Biomark Insights"},{"issue":"6","key":"2024051415260935800_bib75","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/15592294.2016.1178432","article-title":"Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: the case of subset #2","volume":"11","author":"Bhoi","year":"2016","journal-title":"Epigenetics"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2217\/2225016\/blooda_adv-2023-010218-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2217\/2225016\/blooda_adv-2023-010218-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:26:47Z","timestamp":1715700407000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/9\/2217\/515233\/C-terminal-binding-protein-2-is-a-novel-tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010218","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}